Theravance Biopharma, Inc. Proceeds from Income Tax Refunds
Theravance Biopharma, Inc. (TBPH) reported Proceeds from Income Tax Refunds of $5.03 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIncomeTaxRefunds · last filed 2018-11-08
- Theravance Biopharma, Inc. proceeds from income tax refunds for the quarter ending 2018-03-31 was $4.47M.
| Period end | Proceeds from Income Tax Refunds 3 month | Proceeds from Income Tax Refunds 9 month |
|---|---|---|
| 2018-09-30 | $5.03M 10-Q · filed 2018-11-08 | |
| 2018-03-31 | $4.47M 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |